CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Phibro Animal Health Q1 sales rise on mineral nutrition demand

By Reuters News


Overview

  • US animal health and mineral nutrition firm's fiscal Q1 net sales rose 6% year-over-year

  • Adjusted diluted EPS for fiscal Q1 increased 8% year-over-year

  • Company maintained full-year financial guidance for fiscal 2027


Outlook

  • Phibro maintains FY 2027 net sales guidance of $1.55 bln to $1.60 bln

  • Company expects FY 2027 adjusted EBITDA of $258 mln to $268 mln

  • Company sees FY 2027 adjusted diluted EPS of $3.41 to $3.59


Result Drivers

  • MINERAL NUTRITION & PERFORMANCE PRODUCTS - Co said higher demand and prices in Mineral Nutrition and increased demand for Performance Products led Q1 growth

  • REGIONAL DEMAND SHIFTS - Increased demand for MFAs in North America and Asia and higher ethanol processing aids sales offset lower virginiamycin sales in Brazil

  • SALES VOLUME & PRICING - Gross profit rose on higher sales volume and average selling prices, partly offset by higher input and distribution costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Sales

$386.8 mln

Q1 Net Income

$29.5 mln

Q1 Adjusted EBITDA

$64.3 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Phibro Animal Health Corp is $49.00, about 30.1% above its November 3 closing price of $37.65

  • The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 3 - Amneal Q3 revenue beats estimates on affordable medicines growth; outlook raised

  • Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.